#AriBio
AriBio Alzheimer's pill slows decline in selected Phase 3 patients, but misses target in full trial #SouthKorea #Health
AriBio Alzheimer's pill slows decline in selected Phase 3 patients, but misses target in full trial
Two patient groups deliver different results AriBio's experimental Alzheimer's pill AR1001 slowed clinical decline by 31% over 52 weeks among 604 trial participants who were not taking established medicines for Alzheimer's symptoms. Across the full study of 1,535 people, however,…
asiadaily.org
November 17, 2026 at 11:50 PM
AriBioのアルツハイマー病治験薬、選定された第3相患者群で進行を抑制 全体集団では目標未達 #韓国 #健康医療
AriBioのアルツハイマー病治験薬、選定された第3相患者群で進行を抑制 全体集団では目標未達
2つの患者群で異なる結果AriBioのアルツハイマー病治験薬AR1001は、アルツハイマー病の症状を抑える既存薬を服用していなかった治験参加者604人で、52週間にわたり臨床症状の悪化を31%抑えた。しかし、1,535人を対象とした試験全体では、プラ…
jp.asiadaily.org
November 18, 2026 at 12:02 AM
Open access link to previous phase 2 trial of AR1001 by AriBio & others:

A phase 2 randomized, placebo-controlled study on the efficacy & safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease.

🧪🧠💊 #medsky
www.sciencedirect.com/science/arti...
www.sciencedirect.com
November 18, 2026 at 11:47 AM
This year's Clinical Trials on Alzheimer's Disease (CTAD) congress in Boston has revealed encouraging data for new drug candidates from the likes of #Biogen and #AriBio, but some disappointments as well. #Alzheimers #CTAD

pharmaphorum.com/news/mixed-r...
Mixed results for experimental Alzheimer's therapies at CTAD
The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
pharmaphorum.com
November 19, 2026 at 11:24 AM
Pílula experimental da AriBio contra o Alzheimer desacelera declínio em pacientes selecionados na fase 3, mas não atinge objetivo no estudo completo #CoreiadoSul #Saúde
Pílula experimental da AriBio contra o Alzheimer desacelera declínio em pacientes selecionados na fase 3, mas não atinge objetivo no estudo completo
Dois grupos de pacientes apresentam resultados diferentes A pílula experimental da AriBio contra o Alzheimer, AR1001, desacelerou o declínio clínico em 31% ao longo de 52 semanas entre 604 participantes do estudo que não tomavam medicamentos já estabelecidos para os…
br.asiadaily.org
November 18, 2026 at 12:02 AM
An erectile dysfunction-style medication slowed cognitive and functional decline by 31% in patients with early Alzheimer's disease who were not taking other dementia treatments.

Developed by South Korean biopharmaceutical company AriBio, the experimental pill, known as AR1001 or…
November 20, 2026 at 2:09 PM
La píldora de AriBio contra el alzhéimer ralentiza el deterioro en un grupo seleccionado de pacientes de fase 3, pero no alcanza el objetivo en el conjunto del ensayo #CoreadelSur #Salud
La píldora de AriBio contra el alzhéimer ralentiza el deterioro en un grupo seleccionado de pacientes de fase 3, pero no alcanza el objetivo en el conjunto del ensayo
Dos grupos de pacientes, resultados diferentes La píldora experimental de AriBio contra el alzhéimer, AR1001, ralentizó el deterioro clínico un 31% en 52 semanas entre 604 participantes del ensayo que no tomaban medicamentos establecidos para los síntomas del alzhéimer. Sin…
es.asiadaily.org
November 18, 2026 at 12:02 AM
www.independent.co.uk headline change

https://www.independent.co.uk/news/uk/home-news/alzheimers-symptoms-treatment-drug-ar1001-aribio-b3086289.html

New text is now
ED pill may have a new use - slowing Alzheimer’s progression
November 17, 2026 at 1:23 PM
“… The South Korean company AriBio, which makes AR1001, said the drug slowed decline in 604 people taking no other drugs for Alzheimer’s. In a wider group of patients taking other drugs, the tablet did not achieve statistically significant results.”

#ddrm
bsky.app/profile/asia...
November 18, 2026 at 6:19 PM
Thirteen items across eleven sources: FDA approval for Roche's oral SERD Wilserdly, EU clearance for an Incyte dermatology pill, Phase 3 wins at AriBio and Sellas, and a record $5B AI-drug-discovery round for Isomorphic Labs.
https://openbionews.com/analysis/daily-bio-news-summary-2026-11-17/
Daily Bio News Summary — 2026-11-17: Approvals, a record AI round and another ADC retrenchment | Data Analysis | OpenBio News
Thirteen items across eleven sources: an FDA nod for Roche
openbionews.com
November 18, 2026 at 3:00 AM
12L/Day Dehumidifier for Home Smart Humidity Control, Digital Display, Laundry & Sleep Modes, 2L Wat...

🔥 Save 15%, was £129.99 now £109.99
buycooling.co.uk/product/12ld...

⌛️ More limited time deals: buycooling.co.uk/deals/

#TopUKDeal #Deal #ARIBIO
12L/Day Dehumidifier for Home Smart Humidity Control, Digital Display, Laundry & Sleep Modes, 2L Water Tank & Drain Hose, 24H Timer, Child Lock, Low Noise Portable Air Dryer for Bedroom, Bathroom
【SUPER OPTIMAL HUMIDITY CONTROL】Tired of excessive damp air in your house? High humidity can cause issues such as wet and smelly clothes, moldy and rotten furniture, and harmful bacteria. Our…
buycooling.co.uk
October 20, 2026 at 3:08 PM
2026-05-14 08:02:55 - Fosun Pharma and Aribio signed a global exclusive option agreement for AR1001, a treatment drug for Alzheimer's disease.
May 14, 2026 at 12:10 AM
[1/5] 2026-05-13 18:33:43 - [Fosun Pharma: Its holding subsidiary signs an exclusive option agreement] Fosun Pharma announced that its holding subsidiary Fosun Pharmaceutical Industries has been granted an exclusive option by AriBio. According to the agreement, AriBio shall provide
May 13, 2026 at 10:41 AM
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape
Alzheimer’s Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape | PressReleaseCC
DelveInsight reports that over 110 key companies are actively engaged in developing more than 120 treatment therapies for Alzheimer’s disease.
www.pressreleasecc.com
November 29, 2025 at 1:12 PM
Mild Cognitive Impairment Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Biogen Inc., Eisai Co., Eli Lilly and Company, Alzheon Inc., AriBio Co., TauRx Therapeutics
www.pressreleasecc.com
October 25, 2025 at 8:45 AM
Fosun Pharma and AriBio Forge Global Alliance for Alzheimer's Treatment#Fosun_Pharma#AriBio#AR1001
Fosun Pharma and AriBio Forge Global Alliance for Alzheimer's Treatment
Fosun Pharma and AriBio have initiated a groundbreaking collaboration for AR1001, an innovative Alzheimer's drug designed to meet urgent medical needs globally.
third-news.com
May 14, 2026 at 3:05 AM
AriBio signs $230 mil. license deal for kidney and liver treatments with US firm - KBR - goo.gl/alerts/g85n1n #GoogleAlerts
AriBio signs $230 mil. license deal for kidney and liver treatments with US firm
AriBio said it signed an exclusive license and commercialization agreement with Restari, a U.S. biotechnology company specializing in renal diseases, for new drug programs targeting kidney and liver c...
goo.gl
January 23, 2026 at 2:44 PM